CFDA to come under national market supervision administration

INICIO/Políticas y legislación | Posted 20/04/2018 post-comment0 Post your comment

A sweeping government restructuring plan was approved by China’s National People’s Congress on 17 March 2018. The reorganization will see China’s drug regulator, the China Food and Drug Administration (CFDA), merged into an overarching market supervision administration.

China FDA V14K13

The State Market Regulatory Administration (SMRA) will merge and undertake the responsibilities previously held by the State Administration for Industry and Commerce (SAIC), General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ), the Certification and Accreditation Administration (CAC), the Standardization Administration of China (SAC) and CFDA.

The changes mean that after five years of directly reporting to China’s State Council, CFDA will no longer be a stand-alone agency. In fact, the agency will cease to exist, with a new China National Drug Administration (CNDA) being established for the regulation of the life sciences and health care, under the supervision of the SMRA.

The authority of the new CNDA will only extend to the provincial level, however, with post-approval marketing and sales monitoring being delegated to municipal and county SMRA departments. This it is hoped will prevent confusion over jurisdiction.

The reorganization plan is the latest in a series of changes over the past two decades. China’s drug regulator started out as a stand-alone agency in 1998 and added food to its name in 2003. It then went under the authority of the National Health Commission in 2008 and became its own entity again in 2013, only to once again come under a higher authority.

Related article
Chinese guidelines for copy biologicals

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Emergo, Endpoints,RAPs,Ropes&Gray

comment icon Comments (0)
Post your comment
Related content
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
INICIO/Políticas y legislación Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
INICIO/Políticas y legislación Posted 08/10/2021
USA BIOSIM Act introduction
02 AA010638
INICIO/Políticas y legislación Posted 17/09/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010